🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,121 results for “ACE” Clear

  1. BARICITINIB, TRIAMCINOLONE ACETONIDE, BARICITINIB, HYDROCORTISONE, Baricitinib, Placebo to match 4 mg tablet, BARICITINIB, HYDROCORTISONE, Hydrocutan Creme 1 %, Placebo to match 2mg tablet, Placebo to match 1mg tablet, Placebo to match 2mg/ml oral suspension

    Eli Lilly Co.

    Atopic Dermatitis

    phase 3 small molecule active

    1 trial

  2. BAX 326

    Takeda Pharmaceuticals International AG

    Hemophilia B

    phase 3 mab completed

    1 trial

  3. BAX 326 (Recombinant factor IX)

    Takeda Pharmaceuticals International AG

    Hemophilia B

    phase 3 mab completed

    1 trial

  4. BAX326

    Takeda Pharmaceuticals International AG

    Hemophilia B

    phase 3 mab completed

    1 trial

  5. BAX855

    Takeda Pharmaceuticals International AG

    Hemophilia A

    phase 3 mab completed

    1 trial

  6. BAY 1841788, NUBEQA 300 mg film-coated tablets, Saruparib, ZYTIGA 250 mg tablets, Xtandi - 40 mg film-coated tablets, ZYTIGA 500 mg film-coated tablets, Placebo to match (PTM) tablets, Abiraterone Teva 500 mg film-coated tablets

    AstraZeneca AB

    Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

    phase 3 small molecule active

    1 trial

  7. BAY 3427080, BAY 3427080 60 mg capsules placebo

    Bayer AG

    Vasomotor symptoms caused by adjuvant endocrine therapy in women with, or at high risk for developing hormone-receptor positive breast cancer

    phase 3 small molecule active

    1 trial

  8. BAY 94-8862, Finerenone, Placebo coated tablet 002 to BAY 948862 coated tablet

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Chronic kidney disease

    phase 3 small molecule active

    1 trial

  9. BAY 94-8862, Placebo to Finerenone 10 film-coated tablets, Placebo to BAY 948862, BAY 948862, Placebo to Finerenone 20 film-coated tablets, Finerenone

    Bayer AG

    Proteinuria, Chronic kidney disease

    phase 3 small molecule active

    1 trial

  10. BEFIZAL L.P. 400 mg, comprimé enrobé à libération prolongée, BEZAFIBRATE LP 400 mg, BEFIZAL 200 mg, comprimé pelliculé, Placebo BEZAFIBRATE 200 mg

    Pari Pharma GmbH

    Subjects with PBC with a non-optimal response to UDCA.

    phase 3 small molecule active

    1 trial

  11. BEFIZAL L.P. 400 mg, comprimé enrobé à libération prolongée, placebo of bezafibrate

    Pari Pharma GmbH

    primary sclerosing cholangitis

    phase 3 small molecule active

    1 trial

  12. BELZUPACAP SAROTALOCAN, Placebo (Sham injection) to Belzupacap Sarotalocan solution for sham injection 0.0 mg/mL, BELZUPACAP SAROTALOCAN

    Aura Biosciences

    Primary Indeterminate Lesions or Small Choroidal Melanoma

    phase 3 small molecule active

    1 trial

  13. BENDAMUSTINE , TOCILIZUMAB , SILTUXIMAB , GEMCITABINE , ANAKINRA , Epcoritamab, DIPHENHYDRAMINE , PARACETAMOL , DEXAMETHASONE , RITUXIMAB , OXALIPLATIN , Epcoritamab

    Genmab A/S

    B-cell Lymphoma

    phase 3 small molecule active

    1 trial

  14. BETAMETHASONE, Placebo of fludrocortisone, HYDROCORTISONE HEMISUCCINATE, Placebo of hydrocortisone, FLUDROCORTISONE

    Pari Pharma GmbH

    Patients admitted to the ICU proven or suspected infection as the main diagnosis.

    phase 3 small molecule active

    1 trial

  15. BEVACIZUMAB, OXALIPLATIN, CALCIUM FOLINATE, FLUOROURACIL, PF-08634404

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  16. BEVACIZUMAB, PARACETAMOL , MK-2870, DEXAMETHASONE, BEVACIZUMAB , -, -, MK-2870, -

    Merck Sharp and Dohme

    Ovarian cancer recurrent

    phase 3 small molecule active

    1 trial

  17. BGB-11417, BGB-11417 placebo, BGB-11417, BGB-11417, BGB-11417, Zanubrutinib

    Beone Medicines Ireland Limited

    relapsed or refractory mantle cell lymphoma (R/R MCL)

    phase 3 small molecule active

    1 trial

  18. BHV-7000, Placebo for BHV-7000, BHV-7000

    Biohaven Bioscience Ireland Limited

    Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures

    phase 3 small molecule active

    1 trial

  19. BHV-8000, DaTSCAN 74 MBq/ml solution for injection, DaTSCAN 74 MBq/ml solution for injection, BHV-8000, Placebo for BHV-8000

    Biohaven Bioscience Ireland Limited

    Early Parkinson’s Disease

    phase 3 small molecule active

    1 trial

  20. BI 1015550, Placebo matching BI 1015550, BI 1015550

    Boehringer Ingelheim International GmbH

    Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

    phase 3 small molecule active

    1 trial

  21. BI 1015550, Placebo matching nerandomilast (BI 1015550)

    Boehringer Ingelheim International GmbH

    Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD)

    phase 3 small molecule active

    1 trial

  22. BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, Placebo

    Boehringer Ingelheim International GmbH

    Obesity

    phase 3 small molecule active

    1 trial

  23. BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, Placebo, BI 456906, BI 456906

    Boehringer Ingelheim International GmbH

    Obesity

    phase 3 small molecule active

    1 trial

  24. BI 456906, BI 456906, BI 456906, BI 456906, Placebo matching products 1 to 7 (pre-filled syringe, filling volume: 0.5 mL), BI 456906, BI 456906, BI 456906

    Boehringer Ingelheim International GmbH

    Obesity

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources